Početna › Difuzna skleroderma › Kalifornija
Kliničke studije za Difuzna skleroderma u državi Kalifornija
9 studija za Difuzna skleroderma traži sudionike na lokacijama u državi Kalifornija.
Gradovi u državi Kalifornija
Službeni tekst studije (engleski)
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
- UCLA, Los Angeles
- Hoag Hospital, Newport Beach
U tijeku regrutacijaFaza 2
Od 18 do 70 godina · Oba spola · Ažurirano 28. ruj 2026. · NCT06470048EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
- EncompaSSc site in La Jolla, CA, La Jolla
- EncompaSSc site in Loma Linda, CA, Loma Linda
- University of California Los Angeles Scleroderma Center, Los Angeles
- i još 2
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 15. ruj 2026. · NCT07287670A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Loma Linda University Medical Center, Loma Linda
U tijeku regrutacijaFaza 1
Od 18 do 74 godina · Oba spola · Ažurirano 10. ruj 2026. · NCT07085104A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
- GSK Investigational Site, Los Angeles
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 9. ruj 2026. · NCT06716606A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- i još 1
U tijeku regrutacijaFaza 2/3
Od 18 godina i više · Oba spola · Ažurirano 8. ruj 2026. · NCT05878717A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- UC San Diego Health, La Jolla
- Stanford University Medical Center, Redwood City
U tijeku regrutacijaFaza 1
Od 18 do 70 godina · Oba spola · Ažurirano 28. kol 2026. · NCT06925542Platform Clinical Study for Conquering Scleroderma
- Keck School of Medicine at USC Medical Center, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Stanford University Medical Center, Palo Alto
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 18. kol 2026. · NCT06195072A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Orange
U tijeku regrutacijaFaza 1/2
Od 18 do 75 godina · Oba spola · Ažurirano 7. kol 2026. · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Chula Vista, Chula Vista
- Artiva Investigational Site Covina, Covina
- Artiva Investigational Site Los Alamitos, Los Alamitos
- i još 3
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 31. srp 2026. · NCT06991114Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.